Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Spanish Real World Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy.

NCT04285866 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT04285866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04285866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Spanish Real World Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy.
Lead sponsor
Fundación GECP
Phase
Observational
Overall status
Completed
Start date
May 21, 2020
Completion date
December 31, 2021
Enrollment
245 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer (sclc)